CurrentHealthfirstPolicy PO-RE-046v4

Nerve Fiber Density Testing

Customize your policy alerts

Sign up for Healthfirst Policy PO-RE-046v4 alerts

Get alerted when Policy PO-RE-046v4 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs coverage criteria for epidermal and sweat-gland nerve fiber density testing (skin biopsy with IENF/ENFD and SGNFD) for evaluation of small-fiber neuropathy and related indications for Healthfirst members.

Policy Summary

PayerHealthfirst

PolicyNerve Fiber Density Testing

Policy CodePolicy PO-RE-046v4

Change TypeAdministrative review — no material changes

Effective DateMay 1, 2026

Last ReviewMar 16, 2026

Next Review Date

Key ActionObtain prior authorization only when all required clinical criteria for epidermal nerve fiber density testing are documented.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentHealthfirstPolicy PO-RE-046v4

Nerve Fiber Density Testing

Customize your policy alerts

Sign up for Healthfirst Policy PO-RE-046v4 alerts

Get alerted when Policy PO-RE-046v4 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerHealthfirst

PolicyNerve Fiber Density Testing

Policy CodePolicy PO-RE-046v4

Change TypeAdministrative review — no material changes

Effective DateMay 1, 2026

Last ReviewMar 16, 2026

Next Review Date

Key ActionObtain prior authorization only when all required clinical criteria for epidermal nerve fiber density testing are documented.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

45–90%IENF sensitivity

≈35,000Approx. biopsies reported

88313–88356Procedure codes listed

Coverage Criteria for Nerve Fiber Density Testing

inv-01: Diagnosis of small-fiber neuropathy (ENFD) — Covered when ALL of the following are met

Covered when ALL of the following are met:

ENFD coverage criteria: a. An individual presents symptoms of painful sensory neuropathy; b. There is no history of a disorder known to predispose painful neuropathy (e.g., diabetic neuropathy, toxic neuropathy, HIV neuropathy, celiac neuropathy, inherited neuropathy); c. Physical examination shows no evidence of findings consistent with large-fiber neuropathy (eg, reduced or absent muscle-stretch reflexes or reduced proprioception and vibration sensation); d. Electromyography and nerve-conduction studies are normal and show no evidence of large-fiber neuropathy.

All four conditions must be documented.

inv-02: Not medically necessary / Not covered — 1 top-level node

Not covered: ENFD measurement from skin biopsy does not meet coverage criteria for all other situations not described in the covered criteria; measurement of sweat gland nerve fiber density does not meet coverage criteria.

Explicit policy exclusions.

inv-03: Guideline-based coverage criteria — Clinical use supported by guideline panels when there is suspicion of small-fiber dysfunction or to confirm/quantify SFN in specific contexts

Clinical use supported by guideline panels when there is suspicion of small-fiber dysfunction or to confirm/quantify SFN in specific contexts:

Guideline-supported indications: Skin biopsy with IENFD measurement may be considered/performed in patients with clinical signs of small-fiber dysfunction or suspected distal symmetric polyneuropathy, particularly small-fiber sensory neuropathy (supported at Level B/C by specialty societies) and may be used for follow-up or to detect treatment response in diabetic SFN.

Sourced from AAN/AANEM/AAPM&R, EFNS/PNS, NeuPSIG, IMMPACT.

Support for multimodal assessment: Guidelines recommend combining skin biopsy/IENFD with autonomic testing and bedside sensory tests; skin biopsy is a validated technique and may be particularly useful when nerve conduction studies are normal.

EFNS/PNS and AAN groups emphasize use alongside other diagnostic modalities.

Measurement of sweat gland nerve fiber density (SGNFD/SGII) from skin biopsy is explicitly excluded by this policy. The policy states: Measurement of sweat gland nerve fiber density DOES NOT MEET COVERAGE CRITERIA.

For Fabry disease, the policy references an international expert panel recommendation that when an accurate diagnostic laboratory test is available, nerve or skin biopsies are not required for diagnosis. Skin biopsy may be used only to detect or quantify small-fiber involvement in otherwise asymptomatic patients.

The revision history documents that literature reviews conducted on 12/03/2025 and 09/04/2024 "did not necessitate any modifications to coverage criteria." This indicates that the current coverage criteria remained unchanged following those reviews.

Epidermal nerve fiber density (ENFD/IENF) measurement from skin biopsy is covered only when all specified diagnostic criteria for small-fiber neuropathy are met; the policy further states that ENFD measurement from skin biopsy does not meet coverage criteria for any situations other than the specified diagnostic criteria. Requests falling outside those documented criteria will be denied.

Guideline panels note that while skin biopsy with IENFD measurement is a validated tool to assess small-fiber neuropathy, skin biopsy has not been useful for identifying the etiology of SFN in many cases. The policy advises that the test’s inability to determine cause should be considered when ordering it for etiologic assessment.

Applicable Codes

Applicable pathology and morphometry CPT codesCPT

88313	Special stain including interpretation and report; Group II, all other (e.g., iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry.
88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure.
88344	Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure.
88346	Immunofluorescence, per specimen; initial single antibody stain procedure.
88350	Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).
88356	Morphometric analysis; nerve.

Applicable Procedure/CPT CodesCPT

88313	Special stain including interpretation and report; Group II, all other (e.g., iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry.
88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure.
88344	Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure.
88346	Immunofluorescence, per specimen; initial single antibody stain procedure.
88350	Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).
88356	Morphometric analysis; nerve.

IENF dorsal foot threshold — <8 fibers/mm

IENF dorsal foot diagnostic thresholdLess than 8 fibers per millimeter (<8 fibers/mm) at the dorsal foot

Reported sensitivity at this thresholdStudy reported sensitivity of 88% for SFSN when using <8 fibers/mm at dorsal foot

Reported specificity at this thresholdStudy reported specificity of 91% for SFSN at this threshold

Provider Requirements, Billing, and Documentation

Prior Authorization

Prior Authorization Required

Approval requires documentation that all listed clinical criteria for the diagnosis of small-fiber neuropathy are met. Prior authorization/coverage determination is only granted when the medical record clearly demonstrates each required element (symptoms of painful sensory neuropathy; absence of disorders known to predispose painful neuropathy; physical exam without signs of large-fiber neuropathy; normal EMG/nerve conduction studies).

All clinical criteria documented in the medical record are required for approval.
Requests lacking documentation of any criterion will be denied.

Note

Use Noninvasive Assessment Prior to Biopsy

Consider noninvasive sensory and autonomic testing prior to or alongside skin biopsy. Bedside sensory testing, quantitative sensory testing, and autonomic function testing (e.g., QSART, heart rate variability) are recommended per professional guidelines to support the clinical evaluation of suspected small-fiber neuropathy.

Perform and document appropriate noninvasive assessments before biopsy when clinically feasible.

Background and Clinical Context

Skin punch biopsy (typically 3 mm) stained with PGP 9.5 is the standard method to quantify intraepidermal/epidermal nerve fiber density (IENF/ENFD) to evaluate small-fiber sensory neuropathy. The procedure is particularly useful when patients have sensory complaints but routine nerve conduction studies and EMG are normal because standard electrophysiologic testing does not assess small unmyelinated fibers. Guideline evidence also supports that a 3-mm distal leg (ankle) skin biopsy is safe with low complication rates.

Definitions

ENFD / IENF definition

TermEpidermal nerve fiber density (ENFD / IENF)

MethodQuantitation of small unmyelinated sensory axons in the epidermis using PGP 9.5 immunohistochemistry on skin biopsy specimens

Sample type3-mm skin punch biopsy specimens (epidermal tissue) stained with PGP 9.5

SGNFD / SGII definition

TermSweat gland nerve fiber density (SGNFD / SGII)

MethodQuantitation of autonomic sudomotor innervation (sweat gland innervation) from skin biopsy preparations

Clinical finding

Policy Summary

PayerHealthfirst

PolicyNerve Fiber Density Testing

Policy CodePolicy PO-RE-046v4

Change TypeAdministrative review — no material changes

Effective DateMay 1, 2026

Last ReviewMar 16, 2026

Next Review Date

Key ActionObtain prior authorization only when all required clinical criteria for epidermal nerve fiber density testing are documented.

SourceLink

On This Page

Include results of autonomic testing in the request to support medical necessity.

Documentation Required

CLIA Compliance Risk for Laboratory-Developed Tests

Laboratory-developed tests (LDTs) for epidermal nerve fiber density and related analyses are regulated under CLIA as high-complexity tests. Lack of proper validation or CLIA-compliant operation may present regulatory and compliance risk for laboratories and affect coverage determinations.

Ensure testing laboratory operates under CLIA and appropriate high-complexity certification.
Maintain validation and quality-control documentation for any LDTs used.

Documentation Required

Specimen and Laboratory Documentation Required

Specimen handling and laboratory documentation must specify the histologic stains and morphometric analyses performed. Requests and claims should include documentation that the following were performed and reported: IENF quantification (site and method), special stains or immunohistochemistry as applicable, and morphometric nerve analysis.

Document biopsy site (e.g., distal leg/ankle), specimen adequacy, and processing methods.
Include specific stains/tests performed (e.g., 88313, 88341, 88342, 88344, 88346, 88350) and morphometric analysis (88356) in the report.
Attach laboratory report with numeric IENF density results and interpretation to support medical necessity.

Documentation Required

Required Clinical Documentation

Documentation must support that all required clinical criteria are met for the diagnosis of small-fiber neuropathy; incomplete records may lead to denial.

Include history, physical exam findings, EMG/nerve conduction study results, and noninvasive testing where performed.
Ensure laboratory reports and pathology documentation are attached to the prior authorization/claim submission.

Reduced SGNFD/SGII reported in diabetic subjects and correlated with sudomotor dysfunction

IENFD / skin biopsy

ProcedureDistal leg (eg, ankle) skin punch biopsy with quantification of linear density of intraepidermal nerve fibers (IENF)

Counting rulesUse generally agreed-upon counting rules for linear density measurement as recommended by EFNS/PNS guidelines

Safety3-mm ankle biopsy described as safe based on ~35,000 biopsies with very low complication rates

Laboratory-developed test (LDT)

DefinitionLaboratory-developed test (LDT): a test developed and validated by a laboratory and performed in-house

RegulationLDTs are regulated by CMS as high-complexity tests under CLIA '88

FDA statusLDTs are not approved or cleared by the U.S. Food and Drug Administration; FDA clearance is not required for clinical use under current policy

Laboratory-developed test (LDT) — in-house definition

Definition (alternate wording)A laboratory-specific test validated and performed in-house and regulated under CLIA '88 as high-complexity testing

Regulatory implicationLack of proper laboratory validation or CLIA compliance may trigger coverage or processing denial

Clinical use noteNot FDA-approved/cleared but permitted for clinical use when validated by the performing laboratory